You need to enable JavaScript to run this app.
Regulatory Recon: FDA's Pazdur Says Too Many Companies Chasing Same Cancer Strategy Merck C. Diff Drug Backed by AdComm (10 June 2016)
Recon
Regulatory News
Michael Mezher